Group 1 - The company held its fifth board meeting on September 3, 2025, with all nine directors present, confirming the meeting's legality and effectiveness [1][2] - The board approved a proposal to jointly invest in a fund with professional investment institutions, establishing the Chengdu Rongchuang Gangtong Equity Investment Fund Partnership with a total subscription amount of RMB 500 million [1][2] - The company will contribute RMB 150 million as a limited partner, representing 30% of the total fund subscription [2]

Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]

Core Viewpoint - The company, 港通医疗, announced the approval of a proposal to jointly invest with professional investment institutions to establish a fund during its fifth board meeting [2] Group 1 - The fifth board meeting of the company took place on September 3, where the investment proposal was reviewed and approved [2]

Core Viewpoint - The company announced a joint investment to establish a fund with several professional investment institutions, indicating a strategic move to enhance its investment capabilities and expand its portfolio [2] Group 1: Investment Details - The company will collaborate with Chengdu Wutong Tree Innovation and Entrepreneurship Investment Partnership, Jianyang Aerospace Industry Investment Development Co., Ltd., Chengdu Technology Transfer Venture Capital Co., Ltd., and Yiyang Enterprise Management (Chengdu) Co., Ltd. to set up the Chengdu Rongchuang Gongtong Equity Investment Fund Partnership [2] - The total subscribed capital of the fund is set at RMB 50 million, with the company contributing RMB 15 million, representing 30% of the total subscribed capital [2] - This investment decision was approved by the company's board of directors and does not require submission to the shareholders' meeting for further approval [2]

Group 1 - The company plans to establish a partnership with several investment firms to create a new equity investment fund with a total subscription amount of RMB 500 million [1] - The company will contribute RMB 150 million, accounting for 30% of the total fund subscription [1] - The investment focus will be on medical devices, medical equipment, and healthcare services, targeting high-end medical devices, AI healthcare, smart wards, smart operating rooms, hospital information systems, robotic-assisted medical services, high-altitude diffusion oxygen supply, and high-end equipment manufacturing [1]

Group 1 - The company, Porton Medical (301515.SZ), announced a joint investment to establish the Chengdu Rongchuang Porton Equity Investment Fund Partnership with several investment firms, with a total subscribed capital of RMB 500 million [1] - The company will contribute RMB 150 million as a limited partner, representing 30% of the total subscribed capital [1] - The investment focus will be on sectors such as medical devices, medical equipment, and medical services, with strategic investments in high-end medical devices, AI healthcare, smart wards, smart operating rooms, hospital information systems, robotic-assisted medical services, plateau diffusion oxygen supply, health management, and high-end equipment manufacturing [1]

格隆汇9月3日丨港通医疗(301515.SZ)公布，公司于2025年9月3日召开第五届董事会第五次会议，审议 通过了《关于与专业投资机构共同投资设立基金的议案》，同意公司与成都梧桐树创新创业投资合伙企 业(有限合伙)(简称"成都梧桐树")、简阳市空天产业投资发展有限公司(简称"空天产投")、成都技转创业 投资有限公司(简称"成都技转")、意扬企业管理(成都)有限责任公司(简称"意扬企管")共同投资设立成都 蓉创港通股权投资基金合伙企业(有限合伙)(暂定名，最终以市场监督管理部门核准的名称为准，简 称"基金""合伙企业")，基金认缴出资总额为人民币50,000万元，其中公司作为有限合伙人以自有资金出 资人民币15,000万元，占基金认缴出资总额的30.00%。 ...

Core Viewpoint - The company has announced the establishment of a new investment fund focused on the medical sector, which is expected to enhance its business operations and financial efficiency [1] Group 1: Investment Details - The company will participate as a limited partner in the Chengdu Rongchuang Gangtong Equity Investment Fund Partnership, contributing RMB 150 million, which represents 30% of the total committed capital of RMB 500 million [1] - The fund aims to invest in areas such as medical devices, medical equipment, and medical services, indicating a strategic focus on expanding into new business domains [1] Group 2: Future Implications - This investment is anticipated to positively impact the company's future development by improving capital utilization efficiency and supporting sustainable growth [1]

证券代码：301515 证券简称：港通医疗 公告编号：2025-055 四川港通医疗设备集团股份有限公司 关于与专业投资机构共同投资设立基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"或"港通医疗"） 于 2025 年 9 月 3 日召开第五届董事会第五次会议，审议通过了《关于与专业投 资机构共同投资设立基金的议案》，同意公司与成都梧桐树创新创业投资合伙企 业（有限合伙）（以下简称"成都梧桐树"）、简阳市空天产业投资发展有限公 司（以下简称"空天产投"）、成都技转创业投资有限公司（以下简称"成都技 转"）、意扬企业管理（成都）有限责任公司（以下简称"意扬企管"）共同投 资设立成都蓉创港通股权投资基金合伙企业（有限合伙）（暂定名，最终以市场 监督管理部门核准的名称为准，以下简称"基金""合伙企业"），基金认缴出 资总额为人民币 50,000 万元，其中公司作为有限合伙人以自有资金出资人民币 15,000 万元，占基金认缴出资总额的 30.00%。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-053 四川港通医疗设备集团股份有限公司 关于2024年第二次回购公司股份进展的公告 二、其他说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召开第四届董事会第十七次会议和第四届监事会第十七次会议，审议通过 《关于 2024 年第二次回购公司股份方案的议案》，公司拟使用不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含）的自有资金和专项回购贷款 资金以集中竞价交易的方式回购公司已发行的人民币普通股（A 股）股票，回购 价格不超过人民币 28.49 元/股（含），回购的股份将用于实施员工持股计划或 股权激励。本次回购股份的实施期限为自公司董事会审议通过本次回购股份方案 之日起不超过 12 个月。具体回购股份的数量以回购期满或回购完毕时公司实际 回购的股份数量为准。 公司于 2024 年 11 月 8 日召开 2024 年第一次临时股东会，审议通过《关于 公司 2024 年前三季度利润分 ...